Cargando…

Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients

Bone biopsy is still the gold standard to assess bone turnover (T), mineralization (M), and volume (V) in CKD patients, and serum biomarkers are not able to replace histomorphometry. Recently, metabolomics has emerged as a new technique that could allow for the identification of new biomarkers usefu...

Descripción completa

Detalles Bibliográficos
Autores principales: Baptista, Aline L, Padilha, Kallyandra, Malagrino, Pamella A, Venturini, Gabriela, Zeri, Ana CM, dos Reis, Luciene M, Martins, Janaina S, Jorgetti, Vanda, Pereira, Alexandre C, Titan, Silvia M, Moyses, Rosa MA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340447/
https://www.ncbi.nlm.nih.gov/pubmed/32666023
http://dx.doi.org/10.1002/jbm4.10372
_version_ 1783555045454774272
author Baptista, Aline L
Padilha, Kallyandra
Malagrino, Pamella A
Venturini, Gabriela
Zeri, Ana CM
dos Reis, Luciene M
Martins, Janaina S
Jorgetti, Vanda
Pereira, Alexandre C
Titan, Silvia M
Moyses, Rosa MA
author_facet Baptista, Aline L
Padilha, Kallyandra
Malagrino, Pamella A
Venturini, Gabriela
Zeri, Ana CM
dos Reis, Luciene M
Martins, Janaina S
Jorgetti, Vanda
Pereira, Alexandre C
Titan, Silvia M
Moyses, Rosa MA
author_sort Baptista, Aline L
collection PubMed
description Bone biopsy is still the gold standard to assess bone turnover (T), mineralization (M), and volume (V) in CKD patients, and serum biomarkers are not able to replace histomorphometry. Recently, metabolomics has emerged as a new technique that could allow for the identification of new biomarkers useful for disease diagnosis or for the understanding of pathophysiologic mechanisms, but it has never been assessed in the chronic kidney disease–mineral and bone disorder (CKD–MBD) scenario. In this study, we investigated the association between serum metabolites and the bone TMV classification in patients with end‐stage renal disease by using serum NMR spectroscopy and bone biopsy of 49 hemodialysis patients from a single center in Brazil. High T was identified in 21 patients and was associated with higher levels of dimethylsulfone, glycine, citrate, and N‐acetylornithine. The receiver‐operating characteristic curve for the combination of PTH and these metabolites provided an area under the receiver‐operating characteristic curve (AUC) of 0.86 (0.76 to 0.97). Abnormal M was identified in 30 patients and was associated with lower ethanol. The AUC for age, diabetes mellitus, and ethanol was 0.83 (0.71 to 0.96). Low V was identified in 17 patients and was associated with lower carnitine. The association of age, phosphate, and carnitine provided an AUC of 0.83 (0.70 to 0.96). Although differences among the curves by adding selected metabolites to traditional models were not statistically significant, the accuracy of the diagnosis according to the TMV classification seemed to be improved. This is the first study to evaluate the TMV classification system in relation to the serum metabolome assessed by NMR spectroscopy, showing that selected metabolites may help in the evaluation of bone phenotypes in CKD–MBD. © 2020 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-7340447
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-73404472020-07-13 Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients Baptista, Aline L Padilha, Kallyandra Malagrino, Pamella A Venturini, Gabriela Zeri, Ana CM dos Reis, Luciene M Martins, Janaina S Jorgetti, Vanda Pereira, Alexandre C Titan, Silvia M Moyses, Rosa MA JBMR Plus Original Articles Bone biopsy is still the gold standard to assess bone turnover (T), mineralization (M), and volume (V) in CKD patients, and serum biomarkers are not able to replace histomorphometry. Recently, metabolomics has emerged as a new technique that could allow for the identification of new biomarkers useful for disease diagnosis or for the understanding of pathophysiologic mechanisms, but it has never been assessed in the chronic kidney disease–mineral and bone disorder (CKD–MBD) scenario. In this study, we investigated the association between serum metabolites and the bone TMV classification in patients with end‐stage renal disease by using serum NMR spectroscopy and bone biopsy of 49 hemodialysis patients from a single center in Brazil. High T was identified in 21 patients and was associated with higher levels of dimethylsulfone, glycine, citrate, and N‐acetylornithine. The receiver‐operating characteristic curve for the combination of PTH and these metabolites provided an area under the receiver‐operating characteristic curve (AUC) of 0.86 (0.76 to 0.97). Abnormal M was identified in 30 patients and was associated with lower ethanol. The AUC for age, diabetes mellitus, and ethanol was 0.83 (0.71 to 0.96). Low V was identified in 17 patients and was associated with lower carnitine. The association of age, phosphate, and carnitine provided an AUC of 0.83 (0.70 to 0.96). Although differences among the curves by adding selected metabolites to traditional models were not statistically significant, the accuracy of the diagnosis according to the TMV classification seemed to be improved. This is the first study to evaluate the TMV classification system in relation to the serum metabolome assessed by NMR spectroscopy, showing that selected metabolites may help in the evaluation of bone phenotypes in CKD–MBD. © 2020 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2020-05-27 /pmc/articles/PMC7340447/ /pubmed/32666023 http://dx.doi.org/10.1002/jbm4.10372 Text en © 2020 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Baptista, Aline L
Padilha, Kallyandra
Malagrino, Pamella A
Venturini, Gabriela
Zeri, Ana CM
dos Reis, Luciene M
Martins, Janaina S
Jorgetti, Vanda
Pereira, Alexandre C
Titan, Silvia M
Moyses, Rosa MA
Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients
title Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients
title_full Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients
title_fullStr Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients
title_full_unstemmed Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients
title_short Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients
title_sort potential biomarkers of the turnover, mineralization, and volume classification: results using nmr metabolomics in hemodialysis patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340447/
https://www.ncbi.nlm.nih.gov/pubmed/32666023
http://dx.doi.org/10.1002/jbm4.10372
work_keys_str_mv AT baptistaalinel potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT padilhakallyandra potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT malagrinopamellaa potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT venturinigabriela potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT zerianacm potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT dosreislucienem potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT martinsjanainas potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT jorgettivanda potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT pereiraalexandrec potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT titansilviam potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients
AT moysesrosama potentialbiomarkersoftheturnovermineralizationandvolumeclassificationresultsusingnmrmetabolomicsinhemodialysispatients